Nesiritide: A reappraisal of efficacy and safety

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 3, 2007, Pages 361-369

  Shah, Sanjiv J ^a   Teerlink, John R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Congestive heart failure; Natriuretic; Nesiritide; Peptide; Renal insufficiency

Indexed keywords

CREATININE; DIURETIC AGENT; DOBUTAMINE; GLYCERYL TRINITRATE; NATRIURETIC FACTOR; NESIRITIDE; NITROPRUSSIDE SODIUM; PLACEBO; VASODILATOR AGENT;

ACUTE HEART FAILURE; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DILATATION; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; GLOMERULUS FILTRATION RATE; HEART CATHETERIZATION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART MUSCLE OXYGEN CONSUMPTION; HEMODYNAMICS; HOSPITALIZATION; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION; LENGTH OF STAY; LOW DRUG DOSE; META ANALYSIS; MORTALITY; PHARMACODYNAMICS; SIDE EFFECT; SURVIVAL TIME; SYSTEMATIC REVIEW; URINE VOLUME;

ANIMALS; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY DISEASES; NATRIURETIC PEPTIDE, BRAIN; RISK FACTORS;

EID: 33847059100     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.3.361     Document Type: Article

References (41)

1. HUNT SA: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. (2005) 46(6):e1-e82.
2. HFSA COMPREHENSIVE HEART FAILURE PRACTICE GUIDELINE SECTION 12: Evaluation and management of patients with acute decompensated heart failure. J. Card. Fail. (2006) 12(1):e86-e103.
3. TEERLINK JR: Overview of randomized clinical trials in acute heart failure syndromes. Am. J. Cardiol. (2005) 96(6A):59G-67G.
4. TORRE-AMIONE G, YOUNG JB, COLUCCI WS et al.: Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol. (2003) 42(1):140-147.
5. O'CONNOR CM, GATTIS WA, ADAMS KF Jr et al.: Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J. Am. Coll. Cardiol. (2003) 41(9):1452-1457.
6. FOLLATH F, CLELAND JG, JUST H et al.: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet (2002) 360(9328):196-202.
7. CUFFE MS, CALIFF RM, ADAMS KF, Jr. et al.: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA (2002) 287(12):1541-1547.
8. COLUCCI WS: Nesiritide for the treatment of decompensated heart failure. J. Card. Fail. (2001) 7(1):92-100.
9. FONAROW GC: B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for heart failure. Heart Fail. Rev. (2003) 8(4):321-325.
10. SACKNER-BERNSTEIN JD, KOWALSKI M, FOX M, AARONSON K: Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA (2005) 293(15):1900-1905.
11. SACKNER-BERNSTEIN JD, SKOPICKI HA, AARONSON KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation (2005) 111(12):1487-1491.
12. IYENGAR S, FELDMAN DS, TRUPP R, ABRAHAM WT: Nesiritide for the treatment of congestive heart failure. Expert Opin. Pharmacother. (2004) 5(4):901-907.
13. ABRAHAM WT, LOWES BD, FERGUSON DA et al.: Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J. Card. Fail. (1998) 4(1):37-44.
14. PUBLICATION COMMITTEE FOR THE VMAC INVESTIGATORS (VASODILATION IN THE MANAGEMENT OF ACUTE CHF): Intravenous nesiritide versus nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA (2002) 287(12):1531-1540.
15. COLUCCI WS, ELKAYAM U, HORTON DP et al.: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N. Engl. J. Med. (2000) 343(4):246-253.
16. MICHAELS AD, KLEIN A, MADDEN JA, CHATTERJEE K: Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation (2003) 107(21):2697-2701.
17. BURGER AJ, HORTON DP, LEJEMTEL T et al.: Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am. Heart J. (2002) 144(6):1102-1108.
18. ADAMS KF, JR., MATHUR VS, GHEORGHIADE M: B-type natriuretic peptide: from bench to bedside. Am. Heart J. (2003) 145(2 Suppl.):S34-S46.
19. LEVIN ER, GARDNER DG, SAMSON WK: Natriuretic peptides. N. Engl. J. Med. (1998) 339(5):321-328.
20. BURGER AJ, BURGER MR: Nesiritide: past, present, and future. Minerva Cardioangiol. (2005) 53(6):509-522.
21. BURGER AJ, SILVER MA: Nesiritide in acute heart failure. Lancet (2003) 362(9388):998; author reply 998-999.
22. ELKAYAM U, AKHTER MW, TUMMALA P, KHAN S, SINGH H: Nesiritide: a new drug for the treatment of decompensated heart failure. J. Cardiovasc. Pharmacol. Ther. (2002) 7(3):181-194.
23. MARCUS LS, HART D, PACKER M et al.: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation (1996) 94(12):3184-3189.
24. WANG DJ, DOWLING TC, MEADOWS D et al.: Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation (2004) 110(12):1620-1625.
25. LAINCHBURY JG, RICHARDS AM, NICHOLLS MG et al.: The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension (1997) 30(3 Pt 1):398-404.
26. JENSEN KT, EISKJAER H, CARSTENS J, PEDERSEN EB: Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin. Sci. (Lond) (1999) 96(1):5-15.
27. NAKAMURA M, ARAKAWA N, YOSHIDA H et al.: Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am. Heart J. (1998) 135(3):414-420.
28. TEERLINK JR: Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Am. Heart J. (2003) 145(Suppl. 2):S26-33.
29. FORMAN DE, BUTLER J, WANG Y et al.: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol. (2004) 43(1):61-67.
30. BUTLER J, FORMAN DE, ABRAHAM WT et al.: Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am. Heart J. (2004) 147(2):331-338.
31. SMITH GL, LICHTMAN JH, BRACKEN MB et al.: Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J. Am. Coll. Cardiol. (2006) 47(10):1987-1996.
32. SMITH GL, VACCARINO V, KOSIBOROD M et al.: Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J. Card. Fail. (2003) 9(1):13-25.
33. BOERRIGTER G, BURNETT JC Jr.: Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications. Curr. Heart Fail. Rep. (2004) 1(3):113-120.
34. HEYWOOD JT: The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail. Rev. (2004) 9(3):195-201.
35. YANCY CW, LOPATIN M, STEVENSON LW, DE MARCO T, FONAROW GC: Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J. Am. Coll. Cardiol. (2006) 47(1):76-84.
36. BUTLER J, EMERMAN C, PEACOCK WF, MATHUR VS, YOUNG JB: The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol. Dial. Transplant. (2004) 19(2):391-399.
37. RITER HG, REDFIELD MM, BURNETT JC, CHEN HH: Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J. Am. Coll. Cardiol. (2006) 47(11):2334-2335.
38. HEBELER RF, OZ MC: Effect of perioperative nesiritide administration on postoperative renal function and clinical outcomes in patients undergoing cardiothoracic surgery. 7th Scientific Forun on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Washington, D.C (2006) Poster 104, abstract 292.
39. PEACOCK WFT, HOLLAND R, GYARMATHY R et al.: Observation unit treatment of heart failure with nesiritide: results from the PROACTION trial. J. Emerg. Med. (2005) 29(3):243-252.
40. ABRAHAM WT, ADAMS KF, FONAROW GC et al.: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J. Am. Coll. Cardiol. (2005) 46(1):57-64.
41. AARONSON KD, SACKNER-BERNSTEIN J: Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA (2006) 296(12):1465-1466.